Skip to main content

Instil Bio, Inc. (TIL)

NASDAQ: TIL · IEX Real-Time Price · USD
18.21 0.08 (0.44%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap2.34B
Revenue (ttm)51,000
Net Income (ttm)n/a
Shares Out128.74M
EPS (ttm)-1.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume123,609
Open18.06
Previous Close18.13
Day's Range17.61 - 18.45
52-Week Range14.42 - 29.49
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorpo...

IndustryBiotechnology
IPO DateMar 19, 2021
Employees307
Stock ExchangeNASDAQ
Ticker SymbolTIL
Full Company Profile

Financial Performance

Financial Statements

News

Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma

Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma

1 month ago - GlobeNewsWire

Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response

2 months ago - GlobeNewsWire

Instil Bio to Present at the Jefferies Virtual Healthcare Conference

DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...

4 months ago - GlobeNewsWire

Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

IPO in March 2021 raising $368M in gross proceeds

5 months ago - GlobeNewsWire

At a Recent Cancer Research Conference, Instil Bio Stole the Show

The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.

5 months ago - The Motley Fool

Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma

DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma...

5 months ago - GlobeNewsWire

Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association...

67% overall response rate and 19% complete response rate in 21 patients

6 months ago - GlobeNewsWire

Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additio...

DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...

7 months ago - GlobeNewsWire

The IPO Market Had A Busy Week

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

7 months ago - Benzinga

Instil Bio Announces Pricing of Upsized Initial Public Offering

DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...

7 months ago - GlobeNewsWire

Cancer biotech Instil Bio files for a $100 million IPO

Instil Bio, an early stage biotech developing cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

7 months ago - NASDAQ

Instil Bio IPO Registration Document (S-1)

Instil Bio, Inc. has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC